Qiagen (NASDAQ:QGEN) Rating Increased to Sell at BidaskClub

Qiagen (NASDAQ:QGEN) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday, October 19th.

A number of other brokerages have also issued reports on QGEN. Commerzbank reissued a “buy” rating on shares of Qiagen in a research report on Monday, September 17th. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 3rd. Barclays reaffirmed a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research report on Thursday, September 6th. Bank of America upped their price objective on Qiagen from $38.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, August 2nd. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research report on Friday, August 3rd. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $39.13.

QGEN traded down $0.48 during trading hours on Friday, reaching $35.97. The company’s stock had a trading volume of 599,414 shares, compared to its average volume of 1,007,009. Qiagen has a fifty-two week low of $30.44 and a fifty-two week high of $39.45.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings data on Monday, October 29th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.02. The business had revenue of $377.90 million during the quarter, compared to analyst estimates of $380.11 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. The company’s revenue was up 3.8% on a year-over-year basis.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. FIL Ltd boosted its stake in Qiagen by 92.4% in the third quarter. FIL Ltd now owns 4,405,352 shares of the company’s stock valued at $166,744,000 after acquiring an additional 2,116,254 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Qiagen during the second quarter worth about $61,777,000. OppenheimerFunds Inc. acquired a new stake in shares of Qiagen during the second quarter worth about $56,507,000. BlackRock Inc. boosted its stake in shares of Qiagen by 28.4% during the second quarter. BlackRock Inc. now owns 6,174,536 shares of the company’s stock worth $223,272,000 after buying an additional 1,365,517 shares during the period. Finally, RTW Investments LP acquired a new stake in shares of Qiagen during the second quarter worth about $19,143,000. Institutional investors own 62.23% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Featured Story: What is a Market Correction?

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply